Comparative Pharmacology
Head-to-head clinical analysis: PARADIONE versus TRIDIONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PARADIONE versus TRIDIONE.
PARADIONE vs TRIDIONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Paradione (paramethadione) is an oxazolidinedione anticonvulsant that suppresses neuronal activity in the motor cortex by increasing the threshold for repetitive neuronal firing and reducing synaptic transmission. Its exact mechanism is unclear but involves modulation of T-type calcium channels and enhancement of GABAergic inhibition.
Increases seizure threshold by modulating voltage-gated sodium channels and enhancing GABA-ergic inhibition.
100 mg orally three times daily; maximum 600 mg/day.
300-600 mg orally three times daily; titrate to seizure control.
None Documented
None Documented
12-24 hours (terminal); prolonged in renal impairment
16-24 hours (trimethadione); dimethadione (active metabolite) has a half-life of ~6-12 days, leading to drug accumulation.
Renal: 70% unchanged; biliary/fecal: 25%; metabolic: 5%
Renal: ~70% as unchanged drug and metabolites (including dimethadione); biliary/fecal: minimal (<10%).
Category C
Category C
Anticonvulsant
Anticonvulsant